Ranbaxy Receives a Letter from the U.S. FDA Related to Paonta Sahib Facility

Tokyo, February 26, 2009 - Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) announced today that its affiliate Ranbaxy Laboratories Limited (NSE/BSE: Ranbaxy/500359; Head Office in Delhi, India) (“Ranbaxy”) had received from the U.S. Food and Drug Administration on February 25, 2009 EST. The letter is related to Ranbaxy’s manufacturing site in India to its manufacturing facility. More details will be disclosed once further analysis is done.